Generic Name and Formulations:
Sevoflurane; volatile liq for inhalation.
Indications for ULTANE:
Induction and maintenance of general anesthesia for surgery.
Adults and Children:
Use sevoflurane calibrated vaporizer. Individualize. Surgical maintenance: usually 0.5–3% sevoflurane with or without nitrous oxide. May be administered with any type of anesthesia circuit. See full labeling for minimum alveolar concentration (MAC) values based on age.
Susceptibility to malignant hyperthermia. Sensitivity to halogenated agents.
To be administered only by those experienced in general anesthesia. Have intubation, artificial ventilation, oxygen and circulatory resuscitation available. Sevoflurane exposure >2 MAC hours at flow rates 1 to <2L/min and fresh gas flow rates <1L/min: not recommended. Renal insufficiency. Severe hepatic impairment. Monitor BP, hepatic and renal function, urine flow during treatment. Neuromuscular disease (eg, Duchenne muscular dystrophy). Susceptible to congenital long QT syndrome. Dessicated CO2 absorbents. Pediatric neurotoxicity risk with repeated or prolonged use. Elderly. Premature infants. Labor & delivery. Pregnancy (Cat.B).
Concomitant KOH containing CO2 absorbents: not recommended. Hyperkalemia with succinylcholine. Potentiated by benzodiazepines, opioids, nitrous oxide. Potentiates neuromuscular blockers (eg, pancuronium, vecuronium, atracurium). Caution with concomitant drugs that prolong the QT interval.
Nausea, vomiting, agitation, somnolence, dizziness, increased salivation, tachycardia, bradycardia, hypotension, cough increased, laryngospasm, airway obstruction, breath holding, shivering, apnea, hypertension; malignant hyperthermia, perioperative hyperkalemia, renal injury (eg, glycosuria and proteinuria); rare: seizures (esp. children), post-op hepatic dysfunction, torsades de pointes, transient elevations in glucose, LFTs, WBC count.
Endocrinology Advisor Articles
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Type 2 Diabetes and Alzheimer Disease: What's the Connection?
- Canagliflozin Trial for T2D With CKD Stopped Early Due to Positive Results
- Treatment With Alemtuzumab May Frequently Induce Thyroid Dysfunction
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Effect of SGLT2 Inhibitors on Heart Failure-Related Hospitalization, Below-Knee Amputation
- Nutraceuticals Containing Equol May Be Effective for Postmenopausal Symptoms
- Conservative Monitoring Strategy for Non-Functioning Pituitary Adenomas Evaluated
- FDA: Some Rx Drugs May Become Available Without Seeing a Doctor
- PM2.5 Contributes to Burden of Diabetes Mellitus Globally